Magnus Financial Group LLC bought a new stake in Amgen, Inc. (NASDAQ:AMGN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,624 shares of the medical research company’s stock, valued at approximately $511,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Oregon Public Employees Retirement Fund lifted its position in shares of Amgen by 20,103.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock valued at $161,000 after acquiring an additional 31,268,677 shares in the last quarter. Capital International Investors lifted its position in shares of Amgen by 301.4% in the third quarter. Capital International Investors now owns 11,093,182 shares of the medical research company’s stock valued at $2,299,506,000 after acquiring an additional 8,329,861 shares in the last quarter. Capital World Investors purchased a new position in shares of Amgen in the third quarter valued at approximately $952,900,000. BlackRock Inc. lifted its position in shares of Amgen by 2.0% in the fourth quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock valued at $8,979,621,000 after acquiring an additional 906,568 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Amgen by 36.2% in the third quarter. AQR Capital Management LLC now owns 2,907,575 shares of the medical research company’s stock valued at $602,711,000 after acquiring an additional 773,506 shares in the last quarter. Institutional investors and hedge funds own 79.18% of the company’s stock.

In other news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total value of $386,360.00. Following the completion of the sale, the director now directly owns 15,092 shares of the company’s stock, valued at $2,915,472.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have sold 6,000 shares of company stock valued at $1,144,120. 0.27% of the stock is owned by insiders.

AMGN stock opened at $193.89 on Thursday. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36. The firm has a market cap of $118.87 billion, a price-to-earnings ratio of 13.46, a price-to-earnings-growth ratio of 2.36 and a beta of 1.21. Amgen, Inc. has a 52-week low of $165.22 and a 52-week high of $210.19.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.26 by $0.16. The company had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same quarter last year, the firm earned $2.89 earnings per share. As a group, equities research analysts anticipate that Amgen, Inc. will post 13.97 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 2.99%. Amgen’s dividend payout ratio (DPR) is 40.28%.

A number of equities analysts recently commented on the company. Oppenheimer set a $224.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Sunday, January 27th. Morgan Stanley reduced their price objective on Amgen from $213.00 to $212.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 19th. Mizuho reiterated a “buy” rating and set a $211.00 price objective on shares of Amgen in a research report on Tuesday, February 26th. BidaskClub downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Finally, Citigroup lifted their price objective on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a research report on Friday, January 4th. Eleven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Amgen presently has a consensus rating of “Hold” and an average price target of $209.00.

WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2019/04/11/2624-shares-in-amgen-inc-amgn-acquired-by-magnus-financial-group-llc.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: Technical Analysis of Stocks and What It Means

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.